ArticleBritish journal of cancer2006
MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.
Article in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.Cancers · 2022Review
- Infantile mediastinal neuroblastoma presenting as an oncologic emergency: usefulness of serum-basedBMJ case reports · 2021Article
- Article
- [Clinical features of neuroblastoma: an analysis of 44 children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020Article
- Bioinformatic Identification of Neuroblastoma Microenvironment-Associated Biomarkers with Prognostic Value.Journal of oncology · 2020Article
- Opportunities and challenges of circulating biomarkers in neuroblastoma.Open biology · 2019Review
- Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL.Cell proliferation · 2019Article
- Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.Biology direct · 2018Article
- Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.Oncotarget · 2017Article
- Article
- The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.Journal of hematology & oncology · 2016Article
- Article
- Surgical treatment of neuroblastoma: twenty-three years of experience at a single institution.Surgery today · 2014Article
- Krüppel-like factor 4 (KLF4) suppresses neuroblastoma cell growth and determines non-tumorigenic lineage differentiation.Oncogene · 2013Article
- Successful treatment of infants with localized neuroblastoma based on their MYCN status.International journal of clinical oncology · 2013Article
- Implications of surgical intervention in the treatment of neuroblastomas: 20-year experience of a single institution.Surgery today · 2012Article
- Article
- Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.Oncogene · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MYCN is the most powerful prognostic factor in cases of older children. However, how MYCN is related to the prognosis of infantile cases is not clear. A mass screening program was carried out by measuring urinary catecholamine metabolites (VMA and HVA) from 6-month-old infants. Of 2084 cases detected by the screening program, MYCN amplification (MNA) was examined by Southern blot analyses in 1533 cases from 1987 to 2000. Of the 1533 cases examined, 1500 (97.8%) showed no MNA, 20 cases (1.3%) showed MNA from three to nine copies, and 13 (0.8%) cases showed more than 10 copies. The 4-year overall survival rates of these three groups (99, 89 and 53%, respectively) were significantly different (P<0.001), indicating that MYCN copy number correlates with the prognosis. Cases with MNA more than 10 copies were more advanced than those without amplification (stage III, IV vs I, II, IVs; P<0.001). Patients with MNA more than 10 copies had significantly higher serum levels of neuron-specific-enolase (NSE) and ferritin than non-amplified patients (P=0.049, P=0.025, respectively). MYCN amplification was strongly correlated with a poor prognosis in infantile neuroblastoma cases. Therefore, for the selection of appropriate treatment, an accurate determination of MNA is indispensable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.